5 Most Oversold Penny Stocks to Buy Right Now

4. Plus Therapeutics, Inc. (NASDAQ:PSTV)

On March 31, 2026, D. Boral Capital downgraded Plus Therapeutics, Inc. (NASDAQ:PSTV) to Hold from Buy ahead of a 1-for-25 reverse stock split effective April 2. D. Boral Capital said the split does not change the company’s enterprise value but noted reverse splits in small-cap biotech “typically signal capital market strain,” can pressure liquidity, and may take time to rebuild the shareholder base.

On March 19, 2026, Plus Therapeutics announced new health economics data evaluating earlier detection and treatment of leptomeningeal metastases using its CNSide cerebrospinal fluid assay. The company said the analysis suggests earlier diagnosis and management may reduce overall healthcare costs by about 40%, driven by earlier intervention, improved treatment precision, and fewer hospitalizations, with results to be presented at the ISPOR 2026 Annual Meeting.

On March 12, 2026, Plus Therapeutics reported Q4 EPS of (29c), compared to the (4c) consensus estimate, with revenue of $5.21M versus $1.23M consensus. CEO Marc Hedrick said the company remains focused on its 2026 targets, highlighting CNSide commercial scale-up and REYOBIQ pivotal trial readiness as key priorities.

Plus Therapeutics, Inc. (NASDAQ:PSTV) develops and commercializes treatments for cancer, including radiotherapeutic candidates targeting central nervous system and other cancers.